Baiyunshan announced that Tianxin Pharmaceutical, a holding subsidiary of the company, recently received the “Drug Supplement Application Approval Notice” for citin choline sodium injections approved and issued by the State Drug Administration. The drug passed the consistent evaluation of the quality and efficacy of generic drugs, and was also approved to increase the 4ml:0.5g specification. In 2025, the sales volume of the drug in domestic public hospitals and online pharmacies was 80.31 million yuan, and Tianxin Pharmaceutical's sales revenue in 2025 was 1.654 million yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.